Metotrexato, yellow powder Ph. Eur., USP
Fornitore: MP Biomedicals
|
Pericolo
|
Synonyms:
(S)-2-(4-(((2,4-Diaminopteridin-6-yl)methyl)(methyl)amino)benzamido)pentanedioic acid
Methotrexate is a cell cycle arresting agent with varying effects. Methotrexate has been reported to arrest the cell cycle in late G1/S thus leading to the inhibition of the synthesis of DNA, RNA, thymidylates, and proteins. The main mechanism of action is reported to involve the inhibition of enzymes involved in purine metabolism which leads to the accumulation of adenosine or the suppression of intercellular adhesion molecule expression by T cells. Additionally, this compound has been observed to inhibit DHFR.
Methotrexate is used for chemotherapy either alone or in combination with other agents. It is effective for the treatment of a number of cancers including: breast, head and neck, leukemia, lymphoma, lung, osteosarcoma, bladder, and trophoblastic neoplasms. It is also used in treatment of autoimmune diseases, ectopic pregnancy, and for the induction of medical abortions. It is used to inhibit dihydrofolate reductase in DHFR-based protein expression systems. Also effective in treatment of pyrimethamine-resistant Plasmodium vivax malaria parasites.
Potent inhibitor of dihydrofolate reductase and agent for antitumor studies. Use to inhibit dihydrofolate reductase in DHFR-based protein expression systems. Also shows immunosuppressive effects in, e.g., rheumatoid arthritis.
Methotrexate is an allosteric inhibititor of dihydrofolate reductase (DHFR), the enzyme that catalyzes the conversion of dihydrofolate to tetrahydrofolate. Since tetrahydrolfolate is required for purine and pyrimidine synthesis, methotrexate treatment results in the inhibition of DNA and RNA synthesis.
- USP and EP Grade
- Practically insoluble in water, ethanol, chloroform and diethyl ether; freely soluble in dilute solutions of alkaline hydroxides and carbonates; soluble in dilute hydrochloric acid.
- Store at + 4 °C. Protect from light.
Methotrexate Content : 98 - 102.0%
Methotrexate is used for chemotherapy either alone or in combination with other agents. It is effective for the treatment of a number of cancers including: breast, head and neck, leukemia, lymphoma, lung, osteosarcoma, bladder, and trophoblastic neoplasms. It is also used in treatment of autoimmune diseases, ectopic pregnancy, and for the induction of medical abortions. It is used to inhibit dihydrofolate reductase in DHFR-based protein expression systems. Also effective in treatment of pyrimethamine-resistant Plasmodium vivax malaria parasites.
|
Formula:
C₂₀H₂₂N₈O₅ Peso molecolare: 454,44 g/mol Temperatura di stoccaggio: Refrigerata |
MDL Number:
MFCD00150847 CAS Number: 59-05-2 UN: 1544 ADR: 6.1,III |
Risultati del test di specificazione
| Identity Test A USP | Passes |
| Identity Test C EP | Passes |
| Identity Test A EP | Passes |
| Identity Test B USP | Passes |
| Identity Test B EP | Passes |
| Specific Rotation (anhydrous basis) USP | +19° to +24° |
| Water USP | ≤12.0% |
| Water EP | ≤13.0% |
| Related Substances EP | Passes |
| (R)-Methotrexate EP | ≤3.0% |
| Heavy Metals EP | ≤50 ppm |
| Sulfated Ash, Residue on Igntion EP, USP | ≤0.1% |
| Organic Impurities USP | Passes |
| Methotrexate Content (anhydrous basis as C20H22N8O5) USP | 98-102.0% |
Learn more
About VWR
Avantor is a vertically integrated, global supplier of discovery-to-delivery solutions for...